Zyversa Therapeutics Stock Investor Sentiment

ZVSA Stock   0.70  0.06  7.76%   
About 54% of ZyVersa Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding ZyVersa Therapeutics suggests that many traders are impartial. The current market sentiment, together with ZyVersa Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ZyVersa Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

ZyVersa Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ZyVersa Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
23 hours ago at www.macroaxis.com         
Acquisition by Finizio Robert G of 132 shares of ZyVersa Therapeutics at 152.46 subject to Rule 16b-...
Macroaxis News
2 days ago at gurufocus.com         
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ...
Gurufocus Stories at Macroaxis
few days ago at thelincolnianonline.com         
Short Interest in ZyVersa Therapeutics, Inc. Declines By 54.6
news
few days ago at thelincolnianonline.com         
Short Interest in ZyVersa Therapeutics, Inc. Declines By 54.6
news
six days ago at news.google.com         
ZVSA stock touches 52-week low at 0.8 amid sharp annual decline - Investing.com
Google News at Macroaxis
over a week ago at globenewswire.com         
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation...
Macroaxis News: globenewswire.com
over a week ago at gurufocus.com         
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces ...
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
ZyVersa Therapeutics prices 2.1M shares at 95c in private placement - TipRanks
Google News at Macroaxis
over a week ago at globenewswire.com         
ZyVersa Therapeutics, Inc. Announces Pricing of 2.0 Million Private Placement Priced At The Market
Macroaxis News: globenewswire.com
over a week ago at news.google.com         
ZyVersa Therapeutics announces pricing of 2M private placement - MSN
Google News at Macroaxis
over a week ago at gurufocus.com         
ZyVersa Therapeutics, Inc. Announces Pricing of 2.0 Million Private Placement Priced At The Market
Gurufocus Stories at Macroaxis
over two weeks ago at globenewswire.com         
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammatio...
Macroaxis News: globenewswire.com
over two weeks ago at news.google.com         
Can ZyVersas Breakthrough Therapy Challenge Semaglutide in Obesity and Heart Failure - StockTitan
Google News at Macroaxis
over two weeks ago at finance.yahoo.com         
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammatio...
Yahoo News
over a month ago at thelincolnianonline.com         
ZyVersa Therapeutics, Inc. Short Interest Update
news
Far too much social signal, news, headlines, and media speculation about ZyVersa Therapeutics that are available to investors today. That information is available publicly through ZyVersa media outlets and privately through word of mouth or via ZyVersa internal channels. However, regardless of the origin, that massive amount of ZyVersa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ZyVersa Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ZyVersa Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ZyVersa Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ZyVersa Therapeutics alpha.

ZyVersa Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 23404 shares by Oconnor Daniel J. of ZyVersa Therapeutics subject to Rule 16b-3
01/31/2025
2
Can ZyVersas Breakthrough Therapy Challenge Semaglutide in Obesity and Heart Failure - StockTitan
03/05/2025
3
ZyVersa Therapeutics announces pricing of 2M private placement - MSN
03/06/2025
4
ZyVersa Therapeutics prices 2.1M shares at 95c in private placement - TipRanks
03/07/2025
5
ZVSA stock touches 52-week low at 0.8 amid sharp annual decline - Investing.com
03/13/2025
6
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association ...
03/18/2025

Complementary Tools for ZyVersa Stock analysis

When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments